Inflammatory Bowel Disease Monitor - 2012 - Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis


Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis – additional results from two controlled studies - February, 2012
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis - January, 2012
Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study - December, 2011
Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study - November, 2011
Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease - October, 2011
Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis - September, 2011
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial - August, 2011
Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study - July, 2011
Enterohepatic helicobacter in ulcerative colitis: potential pathogenic entities? - June, 2011
Genetics in twins with Crohn’s disease: less pronounced than previously believed? - May, 2011
Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease - April, 2011
The role of Candida in inflammatory bowel disease. Estimation of transmission of C. albicans fungi in gastrointestinal tract based on genetic affinity between strains - March, 2011
A population-based study of health-care resource use among infliximab users - February, 2011
Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts - January, 2011
Clinical utility of measuring infliximab and human antichimeric antibody concentrations in patients with inflammatory bowel disease - December, 2010
Nationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis - November, 2010
Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology - October, 2010
Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males - September, 2010
Infliximab, azathioprine, or combination therapy for Crohn’s disease - August, 2010
Genome-wide association identifies multiple ulcerative colitis susceptibility loci - July, 2010
Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse - June, 2010
Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis - May, 2010
Crohn’s disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly - April, 2010
Characterization of single-nucleotide polymorphisms relevant to inflammatory bowel disease in commonly used gastrointestinal cell lines - March, 2010
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab - February, 2010
Paediatric inflammatory bowel disease during a 44-year period in Copenhagen County: occurrence, course and prognosis – a population-based study from the Danish Crohn Colitis Database - January, 2010
A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn’s disease - September, 2009
Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis - October, 2009
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis - November, 2009

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

February 23, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

Inflammatory Bowel Disease Monitor

» Advanced search

Paper of the Month - January, 2012

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis

Colombel JF, Rutgeerts P, Reinisch W et al.

View Archive »

READER POLL

WEB LINKS

Post Page On

SUBMIT AN ARTICLE


0 rating

February 23, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

Inflammatory Bowel Disease Monitor » Advanced search